C. difficile spores are highly resistant to desiccation, chemicals and extreme temperature. Spores frequently contaminate the environment around patients with CDI, potentially persisting for ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

[43] Fewer treatment failures occurred with vancomycin use, but the difference was not significant. Relapse rates were also similar between treatment groups. Cost differences should be considered ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.

Dr. Thomas Louie of University of Calgary, Canada, principal investigator for this study, stated: “Treatment of C. difficile infection remains in urgent need of agents that spare normal gut ...

Once C-diff is in the ascendancy it can be very hard to shift – the traditional treatment is antibiotics but a significant number of patients do not respond and are left with relentless and ...